TRP2-electroporated autologous dendritic cell therapy(Memorial Sloan Kettering Cancer Center)

N/A

Report date: 2023/01/01 09:47:43

Base Information

Drug NameTRP2-electroporated autologous dendritic cell therapy(Memorial Sloan Kettering Cancer Center)
Drug Alias NameTRP-2 mRNA-electroporated LCsLangerhans-type dendritic cells
ClassificationCell and gene therapy > Cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesMemorial Sloan Kettering Cancer Center
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A